Results 51 to 60 of about 46,900 (298)
, 2017 Background: Saxagliptin has been reported to be associated with an increased risk of hospitalization for heart failure (HF). The objective of this study was to test whether the increased risk is drug specific or a class effect for dipeptidyl peptidase-4 (
賴美淑;張家勳;莊立民;張以承;林昭維 +1 more
core +1 more source
Discrimination based on Gly and Arg/Ser at position 673 between dipeptidyl-peptidase (DPP) 7 and DPP11, widely distributed DPPs in pathogenic and environmental gram-negative bacteria [PDF]
, 2012 Porphyromonas gingivalis, an asaccharolytic gram-negative rod-shaped bacterium, expresses the novel Asp/Glu-specific dipeptidyl-peptidase (DPP) 11 (Ohara-Nemoto, Y. et al. (2011) J. Biol. Chem. 286, 38115–38127), which has been categorized as a member of
Rouf, Shakh M.A. +5 more
core +1 more source
Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong. [PDF]
, 2023 The risk of new onset depression associated with sodium-glucose co-transporter 2 inhibitor (SGLT2I) use in patients with type 2 diabetes mellitus (T2DM) remains unclear.
Li, Lifang +8 more
core +1 more source
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
Fibrogenesis & Tissue Repair, 2016 Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect against DN. In fact, the kidney is the organ where the
Shi, Sen, Koya, Daisuke, Kanasaki, Keizo
openaire +2 more sources
Al-Mustansiriyah Journal of Pharmaceutical Sciences, 2013 Until 1995, only two options for pharmacologic treatment were available for patients with diabetes; sulfonylurea (for type 2 DM only) and insulin (for type 1 or 2).
Hassan Mohammed Abbas Al-Temimi +2 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley +1 more source
Dipeptidyl peptidase-4 (DPP-4) inhibitors effects on the cardiovascular system [PDF]
, 2021 The article presents literature review dwelling on the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors hypoglycemic drugs (saxagliptin, alogliptin, sitagliptin, linagliptin, vildagliptin) on cardiovascular outcomes.
Бакуринских, А. А. +5 more
core
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin [PDF]
Diabetes & Metabolism Journal, 2016 BackgroundWe compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes ...
Jong Ho Kim +16 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić +7 more
wiley +1 more source
SAGE Open MedicineBackground: Sodium glucose cotransporter 2 inhibitors are recommended for the treatment of heart failure due to their cardioprotective effects, despite primarily being used as antidiabetic medications. However, the comparative profile of two antidiabetic
Abhigan Babu Shrestha +13 more
doaj +1 more source